Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 8/20 | 0.41 |
| ▸ | CYP26B1 | Q9NR63 | 6/20 | 0.41 |
| ▸ | RXRA | P19793 | 12/20 | 0.40 |
| ▸ | RXRG | P48443 | 4/20 | 0.40 |
| ▸ | RXRB | P28702 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | RARA | P10276 | 3/20 | 0.37 |
| ▸ | RARB | P10826 | 3/20 | 0.37 |
| ▸ | RARG | P13631 | 3/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095481 | 0.79 | RXRA (0.57) | CYP26A1CYP26B1RXRARXRGRXRB | |
| SCHEMBL6730217 | 0.79 | RXRA (0.57) | CYP26A1CYP26B1RXRARXRGRXRB | |
| SCHEMBL7799673 | 0.79 | RXRA (0.50) | CYP26A1CYP26B1RXRARXRGRXRB | |
| SCHEMBL6740646 | 0.78 | CYP26A1 (0.41) | CYP26A1CYP26B1RXRARXRGRXRB | |
| SCHEMBL7794064 | 0.77 | RARB (0.41) | CYP26A1CYP26B1RXRARXRGRXRB | |
| SCHEMBL7771769 | 0.77 | RXRA (0.44) | CYP26A1CYP26B1RXRARXRGRXRB | |
| SCHEMBL3550976 | 0.76 | RARB (0.47) | CYP26A1CYP26B1RXRARARARARB | |
| SCHEMBL6734636 | 0.76 | CYP3A4 (0.51) | CYP26A1CYP26B1RXRARXRGRXRB | |
| SCHEMBL7769521 | 0.75 | PPARG (0.40) | CYP26A1CYP26B1RXRARXRGRXRB | |
| SCHEMBL7799679 | 0.75 | CYP26B1 (0.42) | CYP26A1CYP26B1RXRARXRGRXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162339-A1 | Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | DIAZ PHILIPPE (FR) | 2004-08-19 | — | — | US | claimed |
| EP-0823903-B1 | HETEROCYCLIC DIARYL COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME, AND USES THEREOF | CT INTERNAT DE RECH S (FR) | 2001-07-18 | — | — | EP | claimed |
| US-5981776-A | FOR USE IN HUMAN OR VETERINARY MEDICINE (DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR AND OPHTHALMOLOGICAL COMPLAINTS IN PARTICULAR), OR ALTERNATIVELY IN COSMETIC COMPOSITIONS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1999-11-09 | — | — | US | claimed |
| EP-0823903-A1 | HETEROCYCLIC DIARYL COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME, AND USES THEREOF | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1998-02-18 | — | — | EP | claimed |
| WO-1997029100-A1 | HETEROCYCLIC DIARYL COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME, AND USES THEREOF | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1997-08-14 | — | — | WO | claimed |
| US-20040162339-A1 | Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | DIAZ PHILIPPE (FR) | 2004-08-19 | — | — | US | disclosed |
| EP-0882033-B1 | BENZOFURAN-ACRYLIC ACID DERIVATIVES AND THEIR USE AS MODULATORS OF RXRS OR RARS RECEPTORS | CT INTERNAT DE RECH S (FR) | 2001-08-16 | — | — | EP | disclosed |
| EP-0823903-B1 | HETEROCYCLIC DIARYL COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME, AND USES THEREOF | CT INTERNAT DE RECH S (FR) | 2001-07-18 | — | — | EP | disclosed |
| US-6030952-A | AS HUMAN AND VETERINARY MEDICINE, PARTICULARLY IN THE TREATMENT OF DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR AND OPHTHALMOLOGIC CONDITIONS, AND IN COSMETIC COMPOSITIONS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIOUES GALDERMA (FR) | 2000-02-29 | — | — | US | disclosed |
| US-5981776-A | FOR USE IN HUMAN OR VETERINARY MEDICINE (DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR AND OPHTHALMOLOGICAL COMPLAINTS IN PARTICULAR), OR ALTERNATIVELY IN COSMETIC COMPOSITIONS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1999-11-09 | — | — | US | disclosed |
| EP-0882033-A1 | BENZOFURAN-ACRYLIC ACID DERIVATIVES AND THEIR USE AS MODULATORS OF RXRS OR RARS RECEPTORS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998024778-A1 | BENZOFURAN-ACRYLIC ACID DERIVATIVES AND THEIR USE AS MODULATORS OF RXRS OR RARS RECEPTORS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1998-06-11 | — | — | WO | disclosed |
| EP-0823903-A1 | HETEROCYCLIC DIARYL COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME, AND USES THEREOF | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1998-02-18 | — | — | EP | disclosed |
| WO-1997029100-A1 | HETEROCYCLIC DIARYL COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME, AND USES THEREOF | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162339-A1 | Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof | TYR, MITF, CYP1B1 | CYP26A1 144/4885CYP26B1 149/4885RXRA 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.